Is moderate-intensity statin plus ezetimibe just as effective as high-intensity statin monotherapy in preventing major cardiovascular events?  

The secondary stroke prevention trial showed that high/moderate-intensity statin therapy combined with ezetimibe and titrated to achieve LDLc <70 were equally effective (compared to goal LDLc <100). Overall, the most important determinant of risk reduction is the achieved LDLc, and so moderate...

There is some evidence that moderate-intensity statin plus ezetimibe is as effective as high-intensity statin therapy in terms of lowering LDL cholesterol and reducing CV events although perhaps not as strong evidence as for high-intensity statin versus placebo or moderate-intensity statin. At the e...

From a stroke perspective, there is some evidence that adding ezetimibe to statin therapy helps achieve lower LDL-C levels. Some smaller studies have also shown decreased carotid intima-media thickness (IMT) and some reduction in cerebrovascular and cardiovascular events; however, the evidence is mi...

The goal of statin therapy is to reduce the LDL below 70. High potency statin, atorvastatin, will usually accomplish this goal. If not, then ezetimibe can be added.